Trial Number
577-25
Condition
Prostate Cancer
Participant Age Range
18 years and older
Participant Gender
Male
Enrolling Participants
Yes
Overview
“A Phase 1b/2a, Multicenter, Open-Label Study of Pocenbrodib as Monotherapy and in Combination with Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 in Participants with Metastatic Castration-Resistance Prostate Cancer (mCRPC)”
This clinical trial is testing a new treatment called Pocenbrodib to see how safe it is and whether it might help men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The study has two parts:
Phase 1b – This part is focused on finding the safest dose of Pocenbrodib when taken by itself. Participants will receive different dose levels to help researchers find the dose that works best—with the fewest side effects and the most potential benefit.
Phase 2a – If the drug is found to be safe, this part will test how well Pocenbrodib works: -On its own, and -In combination with other approved cancer treatments, including: Abiraterone acetate (a hormone therapy), Olaparib (a targeted therapy), and 177Lu-PSMA-617 (a type of targeted radiation therapy).
Each treatment group will be studied separately to see how safe and effective the drug is in different combinations.
Who Can Join? Men with prostate cancer that has spread and has stopped responding to standard hormone treatments may be eligible to participate.